Bipolar disorder (BPD) is a spectrum disorder that encompasses two symptom domains: mania and depression. BPD treatment is usually initiated with atypical antipsychotics and antiepileptic drugs (AEDs); their long-standing stronghold as patient-share leaders contributes to the challenges that branded therapies face entering this crowded generic market. However, treatments with the potential to sufficiently address mania and depression will drive growth of the market. Newer-to-market therapies (e.g., Allergan/Gedeon Richter’s Vraylar/Reagila, Lundbeck/Otsuka Pharmaceutical’s Rexulti/RXulti) continue to be incorporated in the treatment paradigm, and emerging therapies (e.g., NeuroRx’s NRX-100/NRX-101) are hoping to demonstrate their ability to fulfill additional unmet needs in BPDtreatment.

Questions Answered:

  • What factors drive and constrain the use of branded atypical antipsychotics in the treatment of BPD? What branded therapy is expected to experience the greatest commercial success during the forecast period?
  • Given the crowded and highly genericized BPDtherapymarket, what is the commercial potential of key late-phase emerging therapies for BPD?
  • What are the greatest areas of unmet need in the treatment of BPD, and how are emerging therapies expected to address these unmet needs?
  • Effective treatment of BPD-associated cognitive impairment is a great unmet need in this market. To what extent will emerging therapies capitalize on this unmet need? How will physicians likely incorporate these treatments into their clinical practice?

Product description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Eighteen country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other DRG research.

Epidemiology: Lifetime prevalence of BPD by country; diagnosed- and drug-treated prevalence of BPD by country.

Emerging therapies: Phase II: 13 drugs; Phase III: 11 drugs; preregistration: 3 drugs; launched: 1 drugs. Coverage of 8 preclinical and Phase I products.

Market forecast features: Ten-year, annualized, patient-based market forecast extending through 2027, segmented by brands/generics.

Key companies: Allergan, Alkermes, AstraZeneca, Eli Lilly, Gedeon Richter, GlaxoSmithKline, Indivior, Janssen, Lundbeck, Minerva Neurosciences, NeuroRx, Noven Pharmaceuticals, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon/Sunovion Pharmaceuticals, Takeda Pharmaceutical.

Key drugs: ALKS-3831, ALKS-5461, aripiprazole, esketamine, lamotrigine IR/XR, Latuda (lurasidone), lithium, lumateperone (ITI-007), NRX-100/NRX-101, , Perseris (risperidone one-month depot, RBP-7000), rapastinel, Rexult/RXulti (brexpiprazole), Risperdal Consta (risperidone microspheres depot), roluperidone (MIN-101), Seroquel IR/XR (quetiapine IR/XR), Trintellix/Brintellix (vortioxetine), Vraylar/Reagila (cariprazine), Wellbutrin IR/SR/XL.

Table of contents

  • Bipolar Disorder - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Audreza Das, P.G. Dip. ; Abey John, MPH

Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group

She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her B.E. degree in Biotechnology from Birla Institute of Technology, a deemed university and her P.G. Diploma in Cancer Immunology & Biotechnology from University of Nottingham.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

Related Reports

Schizophrenia - Special Topics - Special Topics: Agitation In Bipolar And Schizophrenia (US)

Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or...

View Details